Actions for CADTH Canadian Drug Expert Committee recommendation [electronic resource] : indication : for the treatment of adults with acquired thrombotic thrombocytopenic purpura. Caplacizumab (Cablivi -- Sanofi-Aventis Canada Inc.).

Email RIS file
Bookmark
Report an Issue

CADTH Canadian Drug Expert Committee recommendation [electronic resource] : indication : for the treatment of adults with acquired thrombotic thrombocytopenic purpura. Caplacizumab (Cablivi -- Sanofi-Aventis Canada Inc.).

Published
[S.l.] : Canadian Agency for Drugs and Technologies in Health, 2020.
Edition
Version: Final.
Access Online

Availability

I Want It
I Want It

Finding items...

Restrictions on Access
License restrictions may limit access.
Genre(s)
Note
Title from content provider.
View MARC record | catkey: 44546057